Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: J Immunother. 2010 Oct;33(8):780–788. doi: 10.1097/CJI.0b013e3181ee6675

Figure 6. CAR-CCR2b ATCs show enhanced anti-tumor effect.

Figure 6

A) ATCs cells were transduced with either CAR (middle panel) or CAR and CCR2b (right panel) and analyzed by FACS for expression of CAR (by F(ab′)2 FITC antibody; y-axis) and CCR2 (CCR2 PE; x-axis) indicating that both T cell populations express equivalent CAR but only CCR2b gene-modified ATCs express CCR2. B and C) SCID mice received an s.c. injection right flank of SK-N-AS modified to express EGFPluc followed by i.v. injection of either CAR (left panel) or CAR-CCR2b (right panel) and measured for tumor growth by bioluminescence on days 0, 8, 18 and 22. CAR-CCR2b ATCs showed significant (P<.05) inhibition of tumor growth compared to ATCs modified with CAR alone.